Edition:
United States

Masimo Corp (MASI.OQ)

MASI.OQ on NASDAQ Stock Exchange Global Select Market

85.84USD
4:00pm EDT
Change (% chg)

$0.01 (+0.01%)
Prev Close
$85.83
Open
$86.02
Day's High
$86.36
Day's Low
$85.39
Volume
177,295
Avg. Vol
329,522
52-wk High
$104.71
52-wk Low
$48.13

Latest Key Developments (Source: Significant Developments)

Masimo sees 2017 revenue about $759 mln
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Masimo Corp :Masimo reports first quarter 2017 financial results.Sees fy 2017 earnings per share about $2.65.Q1 earnings per share $0.82.Sees fy 2017 revenue about $759 million.Q1 revenue $186.3 million versus i/b/e/s view $184.1 million.Q1 earnings per share view $0.60 -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $2.33, revenue view $753.1 million -- Thomson Reuters I/B/E/S.  Full Article

Masimo announces amendment to settlement agreement between company and Nellcor
Friday, 2 Sep 2016 09:00am EDT 

Masimo Corp: Announced an amendment to existing settlement agreement initially reached between Masimo and Nellcor in January 2006 .Under amendment, Medtronic will continue to pay co royalty of 7.75% for current pulse oximetry products sold in U.S. through October 6, 2018.  Full Article

Masimo Corp reports Q2 GAAP earnings per share $0.57
Wednesday, 3 Aug 2016 04:05pm EDT 

Masimo Corp : Sees FY 2016 revenue about $689 million . Q2 earnings per share view $0.41 -- Thomson Reuters I/B/E/S . Masimo reports second quarter 2016 financial results . Q2 GAAP earnings per share $0.57 . Q2 revenue $172.6 million versus I/B/E/S view $166 million . Sees FY 2016 gaap earnings per share $2.01 .FY 2016 earnings per share view $1.83, revenue view $678.1 million -- Thomson Reuters I/B/E/S.  Full Article

Masimo Corp gives FY 2016 guidance
Tuesday, 23 Feb 2016 04:05pm EST 

Masimo Corp:Expects FY 2016 total product revenues to be approximately $670.0 million including approximately $640.0 million in product revenues and $30.0 million in royalty revenues.expects FY 2016 GAAP earnings per diluted share to be approximately $1.69.Due to the impact of foreign exchange rates and various other non-GAAP adjustments, Masimo also expects FY 2016 non-GAAP earnings per diluted share to be approximately $1.74.  Full Article

Masimo Corp raises FY 2015 guidance
Thursday, 5 Nov 2015 04:05pm EST 

Masimo Corp:Expects FY 2015 total revenues to be approximately $627 million, up from $621 million.Expects FY 2015 product revenues to be approximately $597 million, up from $592 million, while royalty revenues are now expected to be $30 million, up from $29 million.Expects FY 2015 GAAP earnings per diluted share to be $1.49, up from $1.43 and expects non-GAAP earnings per diluted share to be approximately $1.67, up from $1.61.FY 2015 revenue of $622 million and EPS of $1.43 - Thomson Reuters I/B/E/S.  Full Article

Masimo announces new five million share repurchase plan
Wednesday, 4 Nov 2015 04:05pm EST 

Masimo Corp:Announcing the Board's authorization of a new 5.0 million share stock repurchase plan.  Full Article

Masimo Corp raises FY 2015 outlook
Tuesday, 4 Aug 2015 04:05pm EDT 

Masimo Corp:Expects FY 2015 total revenues to be approximately $621 million, up from $608 million.Expects FY 2015 GAAP earnings per diluted share to be $1.43, up from $1.33.Expects FY 2015 non-GAAP earnings per diluted share to be approximately $1.61.FY 2015 revenue of $613 million and EPS of $1.36 - Thomson Reuters I/B/E/S.  Full Article

Masimo Corp gives Q2 2015 guidance above analysts' estimates
Tuesday, 21 Jul 2015 09:00am EDT 

Masimo Corp:Expects Q2 2015 revenues to range from $155.0 million to $156.0 million.Estimates Q2 2015 fully-diluted GAAP earnings per share to be between $0.35 and $0.36.Q2 2015 revenue of $147.9 million and EPS of $0.30 - Thomson Reuters I/B/E/S.  Full Article

Masimo Corp Receives CE Mark for MightySat Rx Pulse Oximeter
Monday, 22 Jun 2015 08:01am EDT 

Masimo Corp:Says CE Mark and full market release of MightySat Rx fingertip pulse oximeter for clinical use in CE countries, offering the same Masimo SET Measure-Through Motion and Low Perfusion(tm) pulse oximetry technology used in the hospitals.  Full Article

More From Around the Web

BRIEF-Masimo CEO Joe Kiani's total compensation in 2016 was $9 mln

* CEO Joe Kiani's total compensation in 2016 was $9 million versus $7.3 million in 2015- SEC filing Source text: [http://bit.ly/2nDDlhw] Further company coverage: